Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > HUGE NEWS : $4 MILLION IN FUNDING FROM NRC

<< Previous

Bullboard Posts

Next >>

Comment by Riverfolkon Apr 07, 2023 9:33am

88 Views

Post# 35384514

RE:RE:RE:RE:HUGE NEWS : $4 MILLION IN FUNDING FROM NRC

Thank you for speaking honestly and with hostility this morning as it lets the readers understand your motives. I will continue to support the facts and provide links to back them up.

As the Prime Minister of Canada states , Arch received funding based on the advice of leading experts in the field.

Prime Minister Trudeau

After showing a signal in the Phase II trials the government reviewed the Data and awarded further funding.

https://archbiopartners.com/2021/12/01/arch-biopartners-lead-drug-lsalt-peptide-to-enter-the-canadian-treatments-for-covid-19-catco-trial/

Last year an Executive from Novo Nordisk joined Arch as a Strategic Advisor

https://archbiopartners.com/2022/10/05/arch-biopartners-adds-farris-smith-as-a-strategic-advisor/

Soon after, the government provided additional funding for the new mechanism of action.

https://archbiopartners.com/2023/02/07/arch-scientist-awarded-cihr-grant-to-study-the-role-of-dipeptidase-1-in-chronic-kidney-disease/

Recently , the government provided 4 million dollars in additional funding to be used for drug manufacturing, dose escalation and additional human trials

https://archbiopartners.com/2023/03/23/arch-biopartners-receives-funding-for-development-of-lsalt-peptide-drug-program/

Have a great day!

<< Previous

Bullboard Posts

Next >>

Understanding tax loss season and the “Santa Claus rally”